1
00:00:00,000 --> 00:00:03,875
Amylin is part of the body’s meal-related signaling.

2
00:00:03,875 --> 00:00:10,542
Cagrilintide was designed as a long-acting amylin analogue, and researchers have tested it for weight

3
00:00:10,542 --> 00:00:14,042
management.

4
00:00:14,042 --> 00:00:17,542
This topic includes human randomized trials.

5
00:00:17,542 --> 00:00:24,625
A phase two study tested cagrilintide alone, while later phase three studies examined a combination with

6
00:00:24,625 --> 00:00:28,125
semaglutide called CagriSema.

7
00:00:28,125 --> 00:00:32,792
The studies reported weight reductions, alongside adverse effects, particularly gastrointestinal

8
00:00:32,792 --> 00:00:39,458
symptoms. A combination’s results cannot be assigned to cagrilintide alone or to an unverified online

9
00:00:39,458 --> 00:00:42,958
product.

10
00:00:42,958 --> 00:00:50,042
At this script’s November 2026 review, the sponsor still described CagriSema as unapproved in the United

11
00:00:50,042 --> 00:00:54,292
States. Regulatory status must be checked again before publication.